On November 16, Albemarle fell 4.53% in Regular Trading, trading at $90.03 per share, with turnover of $27.2592 million.
The clearest catalyst was continued pressure from sell-side target price reductions following the company’s latest quarterly report, even though third-quarter results slightly topped expectations.
Albemarle reported adjusted EPS of $2.58 on revenue of $1.553 billion for the quarter reported on November 4, ahead of consensus estimates near $2.54 and $1.517 billion. However, analysts continued to lower valuation targets afterward, including Rothschild & Co Redburn to $86 from $100 on November 12, Morgan Stanley to $105 from $161 on November 9, and RBC to $119 from $129 on November 6, indicating that better near-term earnings have not fully changed cautious views on the company’s medium-term fundamentals.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments